{
    "id": 30179,
    "fullName": "AKT2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AKT2 positive indicates the presence of the AKT2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 208,
        "geneSymbol": "AKT2",
        "terms": [
            "AKT2",
            "HIHGHH",
            "PKBB",
            "PKBBETA",
            "PRKBB",
            "RAC-BETA"
        ]
    },
    "variant": "positive",
    "createDate": "05/21/2019",
    "updateDate": "05/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17050,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT2 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT2 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT2 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32306,
            "profileName": "AKT2 pos NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34512,
            "profileName": "AKT1 pos AKT2 pos BCL2 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}